Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The global small molecule prefilled syringes market, by Drug Class (Cardiovascular Drugs, Neurology Drugs, Analgesics, Adjuvants, and Others), By Material (Glass and Plastic & Polymer), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 13,749.4 million in 2016 and is expected to exhibit a CAGR of 4.6% over the forecast period (2017-2025).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1629
The increasing availability of small molecule prefilled syringe products (generic as well as branded) and advantages offered by prefilled syringes over conventional dosage forms (instant effect) such as tablets and capsules are expected to drive growth of the market over the forecast period. Moreover, increasing adoption of small molecule prefilled syringe products are further expected to fuel growth of the small molecule prefilled syringes market.
In addition, market players are focusing on capitalizing on patent losses to launch generic versions in the market. For instance, in 2017, Mylan N.V. launched generic alternative of Copaxone 40 mg/ml for multiple sclerosis patients in the U.S. Similarly, in January 2018, Mylan N.V. launched Brabio, first generic alternative to Copaxone 40 mg/ml, for multiple sclerosis patients in the U.K. In 2014, Teva Pharmaceuticals enhanced presence in Multiple Sclerosis segment through the introduction of three-times-a-week Copaxone 40 mg/mL product in the U.S. Moreover, in 2015, Teva Pharmaceuticals launched Generic Lovenox in the U.S. market. Furthermore, in 2016, Fresenius Kabi launched Ketorolac injection in its ready-to-administer prefilled glass syringe. Additionally, in February 2018, Sandoz received the U.S. Food & Drug Administration approval and launched its Glatopa (Glatiramer acetate) 40 mg/mL.
Browse 34 Market Data Tables and 55 Figures spread through 161 Pages and in-depth TOC on Small Molecule Prefilled Syringes Market, by Drug Class (Cardiovascular Drugs, Neurology Drugs, Analgesics, Adjuvants, and Others), By Material (Glass, and Plastic & Polymer), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2025.
To know the latest trends and insights prevalent in the small molecule prefilled syringes market Press Release, click the link below: https://bit.ly/33DXS7Z
Additionally, major players in the market are focusing on adopting growth strategies such as collaborations, acquisitions, agreements, and partnerships, in order to strengthen their market position. For instance, in 2013, Unilife Corporation entered into a long term supply contract with Sanofi S.A. The objective of this contract was to utilize Unilife’s Unifill Finesse platform of prefilled syringes with Sanofi S.A.’s Enoxaparin Sodium, which is sold under brand names such as Lovenox and Clexane. Moreover, in 2015, Pfizer, Inc. acquired Hospira, Inc, a leading provider of injectable drugs and infusion technologies. This acquisition helped the company to increase its market share. Similarly, in 2016, Fresenius Kabi USA acquired BD Rx business from Becton, Dickinson, and Company. The business included pharmaceutical manufacturing plant and the BD Simplist line of seven drugs in ready-to-administer prefilled glass syringes.
Key Takeaways of the Small Molecule Prefilled Syringes Market:
- The global small molecule prefilled syringes market is expected to exhibit a CAGR of 4.6% over the forecast period (2017-2025), attributed to increasing number of product launches by key players such as Mylan N.V., and Fresenius Kabi, AG
- Availability of small molecule therapies in neurology segment is very low, therefore the segment has high growth potential, over the forecast period
- In neurology drugs segment, major drug such as Copaxone, manufactured by Teva Pharmaceutical Industries Ltd. is expected to face competition from generics
- Key players operating in the small molecule prefilled syringes market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Becton, Dickinson, and Company, and Fresenius Kabi AG
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1629
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027